Outcomes of first-line empirical Helicobacter pylori eradication therapy in Austria – data from the European Registry on the Management of H. pylori Infection (Hp-EuReg)
Zeitschrift für Gastroenterologie · 01.05.2026 · 64 (05) · e144-e145
DOI: 10.1055/s-0046-1823091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2026. Verfasst von A Blesl und 16 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
In Austria, Helicobacter pylori (H. pylori) prevalence is≈25%, with clarithromycin resistance around 16%. Eradication rates>90% are required to justify empirical first-line regimens, but recent national data are lacking. Material and Methods Multicenter, prospective European registry evaluating real-world management of H. pylori infection (Hp-EuReg). Austrian patients receiving empirical first-line H. pylori eradication treatment (December 2022-January 2026) were included. Data were recorded via AEG-REDCap e-CRF. Modified intention-to-treat (mITT) analyses were performed.
Results
Overall, 460 first-line patients (53% female, mean age 54±15 years) were included. Main indications were dyspepsia (57%), gastric cancer prevention (14%), gastroduodenal ulcer disease (8%) and unexplained iron deficiency (7%). H. pylori was mainly diagnosed by histology (90%), and post-treatment eradication was most frequently assessed using the 13C-urea breath test (54%) and the stool antigen test (24%). The most commonly prescribed regimens were non-bismuth quadruple concomitant therapy with proton pump inhibitor (PPI)-amoxicillin-clarithromycin-metronidazole (concomitant-ACM) (70%), three‐in‐one single‐capsule therapy (Pylera), consisting of bismuth-tetracycline-metronidazole plus a PPI (16%), and standard triple therapy with PPI-amoxicillin-clarithromycin (triple-AC) (5%). Treatment duration was 14 days in 55% of patients, 10 days in 40%, and 7 days in 5%. PPIs were used at low, standard and high doses in 88%, 5% and 7%, respectively. Overall eradication rate was 89%; concomitant-ACM and Pylera achieved 90% and 92%, respectively, while triple-AC reached 80%. Eradication rates increased with longer treatment duration (90% for 14-day regimens, 88% for 10-day regimens, and 84% for 7-day regimens) and were 89%, 100%, and 87% with low-, standard-, and high-dose PPIs. Compliance was high (95%). Adverse events were reported in 27% of patients, with diarrhoea and nausea being the most frequent (10% and 6%, respectively). Severe adverse events (0.7%) were all anaphylactic reactions.
Conclusion
Concomitant-ACM and Pylera achieved optimal eradication rates (≥90%) in Austria, supporting their use as empirical first-line options. Publication History Article published online: 08 June 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Blesl, A., Tiefenthaller, A., Kienbauer, M., Heeren, S., Dinkhauser, P., Steidl, K., Megymorecz, S., Bergmeister, P., Schreiner, P., Zollner, A., Meyer, M., Singla, A., Farres, O., Parra, P., Moreira, L., Nyssen, O. P., & Gisbert, J. P. (2026). Outcomes of first-line empirical Helicobacter pylori eradication therapy in Austria – data from the European Registry on the Management of H. pylori Infection (Hp-EuReg). Zeitschrift für Gastroenterologie, 64(05), e144-e145. https://doi.org/10.1055/s-0046-1823091
Vancouver
Blesl A, Tiefenthaller A, Kienbauer M, Heeren S, Dinkhauser P, Steidl K, et al. Outcomes of first-line empirical Helicobacter pylori eradication therapy in Austria – data from the European Registry on the Management of H. pylori Infection (Hp-EuReg). Zeitschrift für Gastroenterologie. 2026;64(05):e144-e145. doi:10.1055/s-0046-1823091
BibTeX
@article{Blesl2026,
author = {Blesl, A and Tiefenthaller, A and Kienbauer, M and Heeren, S and Dinkhauser, P and Steidl, K and Megymorecz, S and Bergmeister, P and Schreiner, P and Zollner, A and Meyer, M and Singla, A and Farres, O and Parra, P and Moreira, L and Nyssen, O P and Gisbert, J P},
title = {Outcomes of first-line empirical Helicobacter pylori eradication therapy in Austria – data from the European Registry on the Management of H. pylori Infection (Hp-EuReg)},
journal = {Zeitschrift für Gastroenterologie},
year = {2026},
volume = {64},
number = {05},
pages = {e144--e145},
doi = {10.1055/s-0046-1823091}
}
EUVIMED